How Compounded Treatments Are Helping Hims & Hers Customers Meet Their Weight Loss Goals

Rhea-AI Summary

Hims & Hers Health (NYSE: HIMS) released a white paper showcasing positive outcomes from their weight loss program. According to the data, customers using oral medication kits lost an average of 7.5 pounds (3.6% of initial body weight) in their first month, while those using compounded GLP-1s lost 9.3 pounds (4.1%). The program shows strong customer satisfaction with 79% reporting met or exceeded expectations and only 13% canceling in the first month. The company's holistic approach includes medication management, nutrition guidance, digital tracking tools, and 24/7 care team access through their app.

Positive

• Customers using compounded GLP-1s achieved 4.1% weight loss in first month
• High customer satisfaction with 79% reporting met/exceeded expectations
• Low discontinuation rate of 13% compared to industry average of 30%
• 90% of customers satisfied with personalized dosing plan
• 87% of customers reporting progress toward weight loss goals

Negative

• None.

Insights

Medical Research Analyst

The white paper reveals compelling clinical outcomes for Hims & Hers' weight loss program. Customers using compounded GLP-1s achieved 4.1% body weight reduction in the first month, with an impressive 87% reporting progress toward their goals. The 13% first-month discontinuation rate is particularly noteworthy, comparing favorably against the industry's typical 30% dropout rate.

The high treatment adherence rate and manageable side effect profile (80% reporting tolerable side effects) suggest a well-optimized treatment protocol. The combination of medication management, lifestyle support and digital tracking tools represents a comprehensive approach that addresses multiple aspects of weight management. These early results indicate strong product-market fit in the growing obesity treatment sector.

Market Research Analyst

This data release strategically positions Hims & Hers in the rapidly expanding weight loss market, where demand for GLP-1 medications has surged. The positive outcomes and high customer satisfaction rates (79% meeting/exceeding expectations) could drive customer acquisition and retention, particularly given the company's competitive pricing advantage in the GLP-1 space.

The holistic approach combining medication with digital support tools addresses key market pain points around treatment adherence and long-term sustainability. With 70% of American adults being overweight or obese, the addressable market is substantial. The strong early results could accelerate market penetration and strengthen the company's position against traditional healthcare providers and emerging digital health competitors.

Hims & Hers today released a white paper on how its customers are thriving and seeing meaningful results through personalized weight loss solutions

SAN FRANCISCO--(BUSINESS WIRE)-- Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today released a white paper entitled “Hims & Hers Weight Loss: A Look at Early Customer Experiences and Outcomes” which outlines how customers are achieving positive outcomes with compounded medications through our weight loss program. Early customer results indicate they are managing side effects well, staying on treatment, and overall feeling healthier.

Data from Hims & Hers Weight Loss: A Look at Early Customer Experiences and Outcomes outlines how customers are achieving positive outcomes within our weight loss program. Early customer results indicate they are managing side effects well, staying on treatment, and overall feeling healthier. (Photo: Business Wire)

The United States is in the midst of an obesity epidemic. 70% of American adults have obesity or are overweight. According to the World Health Organization (WHO), at least 2.8 million people die each year due to being overweight or obese. To help solve the obesity crisis in America, successful weight loss solutions are critical to helping patients prosper. We need weight loss solutions that can meet intense ongoing consumer demand, are cost-effective, and are tailored to individuals’ unique needs and sensitivities.

“We are laser focused on increasing access to world-class personalized care in the highest impact areas of health and wellness,” said Dr. Patrick Carroll, Chief Medical Officer of Hims & Hers. “With over 40% of our nation’s adults considered obese our country demands that we use our expertise, size, and industry leadership to answer the very real obesity crisis in the United States and be a part of the solution for the millions of Americans who have obesity and are looking for help.”

According to data highlighted in the company’s latest white paper, research shows that Hims & Hers weight loss solutions are helping customers achieve positive health outcomes. Key findings include:

• Customers using oral medication kits on average, lost 7.5 pounds - approximately 3.6% of their initial body weight - in their first month.
• Customers using compounded GLP-1s lost an average of 9.3 pounds - approximately 4.1% of their initial body weight - in their first month.
• 79% of compounded GLP-1 customers reported that their treatment experience had met or exceeded their expectations.
• 90% of compounded GLP-1 customers are satisfied with their personalized dosing plan and 87% reported they are progressing towards their weight loss goal, very close to meeting their weight loss goal, or had already achieved their weight loss goal.

The research also suggests that Hims & Hers’ weight loss offering is sustainable, allowing its customers to stay on their treatments and achieve lasting results.

• Only 13% of compounded GLP-1 customers cancel their treatment subscription in the first month. This is significant when compared to a recent Blue Cross Blue Shield finding that over 30% of commercially insured adults prescribed GLP-1 treatment discontinue within the first four weeks, which may be because of discomfort with early side effects, the high cost of certain weight loss treatments, and limited access to care.
• 80% of compounded GLP-1 customers who report side effects like nausea say the side effects are tolerable, indicating they plan to continue their treatment, despite mild side effects.

Since December 2023, Hims & Hers has provided its customers access to weight loss solutions. The Hims & Hers program offers a holistic, cost-effective, and personalized approach to reducing weight that includes:

• Medication management: Following consultation with a licensed healthcare provider on the platform, patients may be prescribed medication that is personalized based upon individual patients’ weight loss goals, medical history, needs, and preferences.
• Nutrition, exercise, and mental health support: Through the Hims & Hers app, patients have access to educational and motivational content that offers nutrition guidance, recipes, exercise recommendations, sleep advice, and mental health support. All content is personalized based on the individual’s lifestyle and appetite profile.
• Digital tracking tools: Through the Hims & Hers app, patients can track their progress, hydration, movement, and sleep.
• 24/7 access to a care team: Individuals can message their care team at any time through the Hims & Hers app.

“The data and insights we have been able to glean through our research show that our customers are having meaningful health outcomes when it comes to weight loss,” said Dr. Jessica Yu, Senior Director of Patient Experience at Hims & Hers. “The data shows our customers are experiencing good weight loss on compounded medications, having manageable side-effects through personalized dosing, suggesting the treatment is sustainable and they are making positive strides towards a healthier future. The importance of these findings is significant as we believe early customer satisfaction and adherence to treatment is likely to enhance long-term outcomes and even more important as we continue to search for ways to manage the obesity crisis in our nation.”

Download the full white paper here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241029420293/en/

jtreadwell@forhims.com

Source: Hims & Hers

FAQ

What are the average weight loss results for HIMS customers using GLP-1 medications?

Customers using compounded GLP-1s lost an average of 9.3 pounds (4.1% of initial body weight) in their first month of treatment.

What is the discontinuation rate for HIMS weight loss program?

Only 13% of compounded GLP-1 customers cancel their treatment subscription in the first month, compared to over 30% industry average.

What features are included in HIMS weight loss program?

The program includes medication management, nutrition and exercise guidance, digital tracking tools, and 24/7 access to a care team through their app.

What is the customer satisfaction rate for HIMS weight loss program?

79% of compounded GLP-1 customers reported their treatment experience met or exceeded expectations, with 90% satisfied with their personalized dosing plan.